Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XLJJW
ADC Name
IMGN-388
Synonyms
CNTO-365; CNTO-95-DM4; IMGN388; CNTO 95-DM4; CNTO 365; IMGN 388
   Click to Show/Hide
Organization
ImmunoGen, Inc.; Centocor, Inc.; Johnson & Johnson
Drug Status
Terminated in phase 1
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Terminated in phase 1
Antibody Name
IMGN-388
  Antibody Info 
Antigen Name
Integrin alpha-V (ITGAV)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Puchem SID
160709266
DrugMap ID
DMSYB83
TTD ID
D07HKV
ChEBI ID
CHEMBL2109633
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT00721669
Phase 1
A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
Undisclosed  NCT00721669
Phase 1
A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Advanced solid tumors.
Administration Dosage
Doses ranging from 5 to 80 mg/m2, every 3 weeks, IV.
Related Clinical Trial
NCT Number NCT00721669  Clinical Status Phase 1
Clinical Description A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
Primary Endpoint
No evidence of activity was observed at the lowest doses (45 mg/m2) evaluated.
Other Endpoint
No evidence of human anti-human antibody formation (data available for doses up to 60 mg/m2.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT00721669  Clinical Status Phase 1
Clinical Description A phase 1 dose-escalation study of IMGN388 in patients with solid tumors.
Primary Endpoint
Five patients (breast,prostate,neuroendocrine,and 2 NSCLC) treated at doses 45 mg/m2 have acheived stable disease for 4 cycles.
References
Ref 1 A phase I dose-escalation study of IMGN388 in patients with solid tumors. Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010) 3058-3058.
Ref 2 A phase I study of IMGN388, an antibody drug conjugate targeting av integrin, in patients with solid tumors.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.